biotech · Fibrostenotic Crohn’s disease · liver cirrhosis · AGMB
Agomab Therapeutics NV
Agomab Therapeutics NV is a biotech organization headquartered in Tel Aviv, USA. It trades on NYSE under ticker AGMB. Primary therapeutic focus areas include Fibrostenotic Crohn’s disease, liver cirrhosis, Fibrostenotic
Tel Aviv, USA HQ
2011 Founded
20 Employees
Public company Type
AGMB · NYSE Ticker
Company details
- Status
- Public
- HQ
- Tel Aviv, USA
- Founded
- 2011
- Employees
- 20
- Programs
- 6
- Drugs
- 2
- Patents
- 4
AGMB101-01-CL-102
Phase 1 · other · liver cirrhosis
AGMB101-01-CL-102 for liver cirrhosis is a Phase 1 program (other) at Agomab Therapeutics NV with 1 ClinicalTrials.gov record(s).
Internal code AGMB101-01-CL-102
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Agomab Therapeutics NV
- Phase
- Phase 1
- Modality
- other
- Indication
- liver cirrhosis
- Status
- active
- Trials
- 1